Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Endocrine tumors

S D Averbuch

    Cancer Chemotherapy and Biological Response Modifiers
    |January 1, 1991
    PubMed
    Summary

    No abstract available in PubMed .

    Related Experiment Videos

    Related Concept Videos

    You might also read

    Related Articles

    Articles linked to this work by shared authors, journal, and citation graph.

    Sort by
    Same author

    Phase I safety, pharmacokinetic, and pharmacodynamic trial of ZD1839, a selective oral epidermal growth factor receptor tyrosine kinase inhibitor, in patients with five selected solid tumor types.

    Journal of clinical oncology : official journal of the American Society of Clinical Oncology·2002
    Same author

    The tyrosine kinase inhibitor ZD1839 ("Iressa") inhibits HER2-driven signaling and suppresses the growth of HER2-overexpressing tumor cells.

    Cancer research·2001
    Same author

    ZD1839 ('Iressa') as an anticancer agent.

    Drugs·2000
    Same author

    Treatment of advanced medullary thyroid carcinoma with a combination of cyclophosphamide, vincristine, and dacarbazine.

    Cancer·1994
    Same author

    New bisphosphonates in the treatment of bone metastases.

    Cancer·1993
    Same author

    Dose-response study of alendronate sodium for the treatment of cancer-associated hypercalcemia.

    Journal of clinical oncology : official journal of the American Society of Clinical Oncology·1993
    Same journal

    Native and genetically engineered anti-disialoganglioside monoclonal antibody treatment of melanoma.

    Cancer chemotherapy and biological response modifiers·2005
    Same journal

    Human tumor associated antigen mimicry by xenoantigens, anti-idiotypic antibodies and peptide mimics: implications for immunotherapy of malignant diseases.

    Cancer chemotherapy and biological response modifiers·2005
    Same journal

    DNA vaccines for melanoma.

    Cancer chemotherapy and biological response modifiers·2005
    Same journal

    Immunizing against partially defined antigen mixtures, gangliosides, or peptides to induce antibody, T cell, and clinical responses.

    Cancer chemotherapy and biological response modifiers·2005
    Same journal

    Chemotherapy, cytokines, and biochemotherapy for melanoma.

    Cancer chemotherapy and biological response modifiers·2005
    Same journal

    Current status of interferon-alpha in the treatment of melanoma.

    Cancer chemotherapy and biological response modifiers·2005
    See all related articles